Our top pick for
Avinger Inc is a medical devices business based in the US. Avinger shares (AVGR) are listed on the NASDAQ and all prices are listed in US Dollars. Avinger employs 69 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$0.72|
|52-week range||$0.21 - $2.67|
|50-day moving average||$0.79|
|200-day moving average||$1.00|
|Wall St. target price||$2.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.24|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-21)||-4.80%|
|1 month (2021-09-28)||-9.27%|
|3 months (2021-07-28)||-24.36%|
|6 months (2021-04-28)||-41.58%|
|1 year (2020-10-28)||186.75%|
|2 years (2019-10-28)||-51.12%|
|3 years (2018-10-26)||0.78|
|5 years (2016-10-28)||3.5|
|Revenue TTM||$10.4 million|
|Gross profit TTM||$2.6 million|
|Return on assets TTM||-32.41%|
|Return on equity TTM||-134.18%|
|Market capitalisation||$67.9 million|
TTM: trailing 12 months
There are currently 1.3 million Avinger shares held short by investors – that's known as Avinger's "short interest". This figure is 5.6% down from 1.4 million last month.
There are a few different ways that this level of interest in shorting Avinger shares can be evaluated.
Avinger's "short interest ratio" (SIR) is the quantity of Avinger shares currently shorted divided by the average quantity of Avinger shares traded daily (recently around 722004.34782609). Avinger's SIR currently stands at 1.84. In other words for every 100,000 Avinger shares traded daily on the market, roughly 1840 shares are currently held short.
However Avinger's short interest can also be evaluated against the total number of Avinger shares, or, against the total number of tradable Avinger shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Avinger's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Avinger shares in existence, roughly 10 shares are currently held short) or 0.014% of the tradable shares (for every 100,000 tradable Avinger shares, roughly 14 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Avinger.
Find out more about how you can short Avinger stock.
We're not expecting Avinger to pay a dividend over the next 12 months.
Avinger's shares were split on a 1:10 basis on 23 June 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Avinger shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Avinger shares which in turn could have impacted Avinger's share price.
Over the last 12 months, Avinger's shares have ranged in value from as little as $0.2139 up to $2.67. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avinger's is 1.7508. This would suggest that Avinger's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Avinger, Inc. , a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.